Jihye Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jihye Kim has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Francis S. Lee
Department of Psychiatry, Weill Cornell Medicine, New York, NY 10065, USA
6 shared publications - Joshua Levitz
Department of Biochemistry and Biophysics, Weill Cornell Medicine, New York, USA
3 shared publications Alexandra B. Fall
Neuroscience Graduate Program, Weill Cornell Medicine; New York, NY, USA
2 shared publicationsDeqiang Jing
Department of Psychiatry, Weill Cornell Medicine, New York, NY 10065, USA
2 shared publications- Guoqing Xiang
Department of Psychiatry, Weill Cornell Medicine
2 shared publications Iva Dincheva
Department of Psychiatry, Columbia University, New York, NY 10032, USA
2 shared publications
Latest Publications
- 11 November 2026
- Published by Society for Neuroscience in The Journal of Neuroscience
- Vol. 46 (45)
From Rapid Synaptic Events to Lasting Antidepressant States: Convergent and Divergent Mechanisms of Ketamine and Psychedelics
Rapid-acting antidepressants have challenged the long-standing view that therapeutic improvement in major depressive disorder requires chronic treatment with monoaminergic agents. Ketamine and classical psychedelics act through distinct proximal targets, yet both can produce rapid and persistent behavioral effects that implicate synaptic and circuit plasticity as the core mechanisms of antidepressant action. This review, based on a minisymposium presented at the 2026 Society for Neuroscience meeting, examines how brief pharmacological perturbations translate into lasting changes in mood-related networks. We first discuss hippocampal mechanisms underlying ketamine action, which include brain-derived neurotrophic factor (BDNF)/tropomyosin receptor kinase B (TrkB)-dependent homeostatic potentiation, TrkB cross talk with metabotropic glutamate receptor 5 (mGluR5) at CA3?CA1 synapses, extracellular signal-regulated kinase (ERK)-dual-specificity phosphatase 6 (DUSP6)-mediated extension of synaptic metaplasticity, and BDNF release at mossy fiber synapses and dentate gyrus neuronal maturation. We then consider how these local plasticity mechanisms interface with distributed circuits that regulate motivation, stress coping, and reward. Across brain regions, emerging work highlights the importance of cell type- and region-specific mechanisms that mediate ketamine's therapeutic actions. We expand on local prefrontal cortical inhibitory cellular signaling dynamics, including the interplay of various G-protein-coupled receptors (GPCRs) in cortical somatostatin interneurons and input-specific adaptations in accumbal circuits. Finally, we compare ketamine with psilocybin, an emerging therapeutic classic psychedelic for treatment-resistant depression that targets the 5-hydroxytryptamine 2A (5-HT2A) receptor primarily. A recurring theme is that an interplay of GPCRs can help shape the timing, localization, and persistence of ketamine-induced neuroplasticity. Together, these studies suggest that antidepressant efficacy arises not from a single pathway or brain region but from coordinated, temporally staged plasticity across molecules, synapses, cells, and circuits.
- 11 November 2026
- Published by Society for Neuroscience in The Journal of Neuroscience
- Vol. 46 (45)
From Rapid Synaptic Events to Lasting Antidepressant States: Convergent and Divergent Mechanisms of Ketamine and Psychedelics
Rapid-acting antidepressants have challenged the long-standing view that therapeutic improvement in major depressive disorder requires chronic treatment with monoaminergic agents. Ketamine and classical psychedelics act through distinct proximal targets, yet both can produce rapid and persistent behavioral effects that implicate synaptic and circuit plasticity as the core mechanisms of antidepressant action. This review, based on a minisymposium presented at the 2026 Society for Neuroscience meeting, examines how brief pharmacological perturbations translate into lasting changes in mood-related networks. We first discuss hippocampal mechanisms underlying ketamine action, which include brain-derived neurotrophic factor (BDNF)/tropomyosin receptor kinase B (TrkB)-dependent homeostatic potentiation, TrkB cross talk with metabotropic glutamate receptor 5 (mGluR5) at CA3?CA1 synapses, extracellular signal-regulated kinase (ERK)-dual-specificity phosphatase 6 (DUSP6)-mediated extension of synaptic metaplasticity, and BDNF release at mossy fiber synapses and dentate gyrus neuronal maturation. We then consider how these local plasticity mechanisms interface with distributed circuits that regulate motivation, stress coping, and reward. Across brain regions, emerging work highlights the importance of cell type- and region-specific mechanisms that mediate ketamine's therapeutic actions. We expand on local prefrontal cortical inhibitory cellular signaling dynamics, including the interplay of various G-protein-coupled receptors (GPCRs) in cortical somatostatin interneurons and input-specific adaptations in accumbal circuits. Finally, we compare ketamine with psilocybin, an emerging therapeutic classic psychedelic for treatment-resistant depression that targets the 5-hydroxytryptamine 2A (5-HT2A) receptor primarily. A recurring theme is that an interplay of GPCRs can help shape the timing, localization, and persistence of ketamine-induced neuroplasticity. Together, these studies suggest that antidepressant efficacy arises not from a single pathway or brain region but from coordinated, temporally staged plasticity across molecules, synapses, cells, and circuits.
- Open Access
Microglial sTREM2 limits dyskinesia and acts on TrkB to support circuit plasticity
Microglia continuously survey the brain and shape neuronal activity, but their contribution to experience-dependent synaptic plasticity is unclear. Levodopa-induced dyskinesia (LID) is a disabling complication of late-stage Parkinson’s disease (PD) that is linked to maladaptive striatal remodeling and is often assumed to reflect detrimental neuroinflammation. Here we identify a dyskinesia-associated microglial gene program in the striatum of PD patients and show that microglia instead act as a protective brake on LID. In a mouse model, microglial depletion exacerbated dyskinesia, whereas microglial repopulation mitigated it. Delivery of AAV expressing soluble TREM2 (sTREM2) similarly reduced LID without impairing the therapeutic benefit of levodopa. Single-nucleus transcriptomics revealed that microglial loss drives extensive remodeling of both direct and indirect spiny projection neurons (SPNs), while repopulation or sTREM2 reverses a large fraction of LID-associated transcriptional changes. Mechanistically, sTREM2 directly engages TrkB and potentiates BDNF-dependent TrkB-ERK signaling, consistent with positive allosteric modulation. Functionally, sTREM2 enhances BDNF-TrkB-dependent hippocampal synaptic plasticity and acutely rebalances striatal dendritic excitability in a compartment- and cell type-specific manner. These findings reveal an unexpected neuroimmune pathway in which microglia restrain maladaptive plasticity via sTREM2-TrkB signaling, with therapeutic implications.
Open AccessMicroglial sTREM2 limits dyskinesia and acts on TrkB to support circuit plasticity
Microglia continuously survey the brain and shape neuronal activity, but their contribution to experience-dependent synaptic plasticity is unclear. Levodopa-induced dyskinesia (LID) is a disabling complication of late-stage Parkinson’s disease (PD) that is linked to maladaptive striatal remodeling and is often assumed to reflect detrimental neuroinflammation. Here we identify a dyskinesia-associated microglial gene program in the striatum of PD patients and show that microglia instead act as a protective brake on LID. In a mouse model, microglial depletion exacerbated dyskinesia, whereas microglial repopulation mitigated it. Delivery of AAV expressing soluble TREM2 (sTREM2) similarly reduced LID without impairing the therapeutic benefit of levodopa. Single-nucleus transcriptomics revealed that microglial loss drives extensive remodeling of both direct and indirect spiny projection neurons (SPNs), while repopulation or sTREM2 reverses a large fraction of LID-associated transcriptional changes. Mechanistically, sTREM2 directly engages TrkB and potentiates BDNF-dependent TrkB-ERK signaling, consistent with positive allosteric modulation. Functionally, sTREM2 enhances BDNF-TrkB-dependent hippocampal synaptic plasticity and acutely rebalances striatal dendritic excitability in a compartment- and cell type-specific manner. These findings reveal an unexpected neuroimmune pathway in which microglia restrain maladaptive plasticity via sTREM2-TrkB signaling, with therapeutic implications.
- Open Access
- 1 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (18) , eaec1444
TrkB/mGluR5 cross-talk underlies a synaptic metaplasticity mechanism of ketamine
A complex ensemble of neuromodulatory receptors orchestrates the many forms of synaptic plasticity that drive behavioral state changes, but an understanding of how such receptors functionally interact is limited. Here, we find that the antidepressant action of ketamine is dependent on both the receptor tyrosine kinase, tropomyosin-related kinase B (TrkB), and the G protein–coupled receptor, metabotropic glutamate receptor 5 (mGluR5). mGluR5 amplifies brain-derived neurotrophic factor (BDNF)–driven signaling of TrkB, enabling synaptic potentiation via “signaling cross-talk,” while BDNF activation of TrkB drives mGluR5 endocytosis via “trafficking cross-talk,” impairing synaptic depression. These modes of cross-talk are enhanced by ketamine, which increases surface and postsynaptic levels of TrkB. Last, we find that an mGluR5 positive allosteric modulator can enhance both modes of cross-talk and boost the effects of ketamine. Together, these data unravel the intimate relationship between different classes of neuromodulatory receptors, revealing that receptor-receptor interplay can drive therapeutic action.
- 1 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (18) , eaec1444
Open AccessTrkB/mGluR5 cross-talk underlies a synaptic metaplasticity mechanism of ketamine
A complex ensemble of neuromodulatory receptors orchestrates the many forms of synaptic plasticity that drive behavioral state changes, but an understanding of how such receptors functionally interact is limited. Here, we find that the antidepressant action of ketamine is dependent on both the receptor tyrosine kinase, tropomyosin-related kinase B (TrkB), and the G protein–coupled receptor, metabotropic glutamate receptor 5 (mGluR5). mGluR5 amplifies brain-derived neurotrophic factor (BDNF)–driven signaling of TrkB, enabling synaptic potentiation via “signaling cross-talk,” while BDNF activation of TrkB drives mGluR5 endocytosis via “trafficking cross-talk,” impairing synaptic depression. These modes of cross-talk are enhanced by ketamine, which increases surface and postsynaptic levels of TrkB. Last, we find that an mGluR5 positive allosteric modulator can enhance both modes of cross-talk and boost the effects of ketamine. Together, these data unravel the intimate relationship between different classes of neuromodulatory receptors, revealing that receptor-receptor interplay can drive therapeutic action.
- 9 April 2025
- Published by Elsevier in Biological Psychiatry
- Vol. 97 (9) , 851-853
Ketamine and Hydroxynorketamine: The Complex Balancing Act Within Fear Neural Ensembles
- 9 April 2025
- Published by Elsevier in Biological Psychiatry
- Vol. 97 (9) , 851-853
Ketamine and Hydroxynorketamine: The Complex Balancing Act Within Fear Neural Ensembles
- 6 September 2023
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 49 (1) , 227-245
The role of neurotrophic factors in novel, rapid psychiatric treatments
Neurotrophic factors are a family of growth factors that modulate cellular growth, survival, and differentiation. For many decades, it has been generally believed that a lack of neurotrophic support led to the decreased neuronal synaptic plasticity, death, and loss of non-neuronal supportive cells seen in neuropsychiatric disorders. Traditional psychiatric medications that lead to immediate increases in neurotransmitter levels at the synapse have been shown also to elevate synaptic neurotrophic levels over weeks, correlating with the time course of the therapeutic effects of these drugs. Recent advances in psychiatric treatments, such as ketamine and psychedelics, have shown a much faster onset of therapeutic effects (within minutes to hours). They have also been shown to lead to a rapid release of neurotrophins into the synapse. This has spurred a significant shift in understanding the role of neurotrophins and how the receptor tyrosine kinases that bind neurotrophins may work in concert with other signaling systems. In this review, this renewed understanding of synaptic receptor signaling interactions and the clinical implications of this mechanistic insight will be discussed within the larger context of the well-established roles of neurotrophic factors in psychiatric disorders and treatments.
- 6 September 2023
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 49 (1) , 227-245
The role of neurotrophic factors in novel, rapid psychiatric treatments
Neurotrophic factors are a family of growth factors that modulate cellular growth, survival, and differentiation. For many decades, it has been generally believed that a lack of neurotrophic support led to the decreased neuronal synaptic plasticity, death, and loss of non-neuronal supportive cells seen in neuropsychiatric disorders. Traditional psychiatric medications that lead to immediate increases in neurotransmitter levels at the synapse have been shown also to elevate synaptic neurotrophic levels over weeks, correlating with the time course of the therapeutic effects of these drugs. Recent advances in psychiatric treatments, such as ketamine and psychedelics, have shown a much faster onset of therapeutic effects (within minutes to hours). They have also been shown to lead to a rapid release of neurotrophins into the synapse. This has spurred a significant shift in understanding the role of neurotrophins and how the receptor tyrosine kinases that bind neurotrophins may work in concert with other signaling systems. In this review, this renewed understanding of synaptic receptor signaling interactions and the clinical implications of this mechanistic insight will be discussed within the larger context of the well-established roles of neurotrophic factors in psychiatric disorders and treatments.
- Open Access
Synaptic plasticity via receptor tyrosine kinase/G protein-coupled receptor crosstalk
Summary: Cellular signaling involves a large repertoire of membrane receptors operating in overlapping spatiotemporal regimes and targeting many common intracellular effectors. However, both the molecular mechanisms and physiological roles of crosstalk between receptors, especially those from different superfamilies, are poorly understood. We find that the receptor tyrosine kinase (RTK), TrkB, and the G protein-coupled receptor (GPCR), metabotropic glutamate receptor 5 (mGluR5), together mediate a novel form of hippocampal synaptic plasticity in response to brain-derived neurotrophic factor (BDNF). Activated TrkB enhances constitutive mGluR5 activity to initiate a mode-switch that drives BDNF-dependent sustained, oscillatory Ca 2+ signaling and enhanced MAP kinase activation. This crosstalk is mediated, in part, by synergy between Gβγ, released by TrkB, and Gα q -GTP, released by mGluR5, to enable a previously unidentified form of physiologically relevant RTK/GPCR crosstalk.
Open AccessSynaptic plasticity via receptor tyrosine kinase/G protein-coupled receptor crosstalk
Summary: Cellular signaling involves a large repertoire of membrane receptors operating in overlapping spatiotemporal regimes and targeting many common intracellular effectors. However, both the molecular mechanisms and physiological roles of crosstalk between receptors, especially those from different superfamilies, are poorly understood. We find that the receptor tyrosine kinase (RTK), TrkB, and the G protein-coupled receptor (GPCR), metabotropic glutamate receptor 5 (mGluR5), together mediate a novel form of hippocampal synaptic plasticity in response to brain-derived neurotrophic factor (BDNF). Activated TrkB enhances constitutive mGluR5 activity to initiate a mode-switch that drives BDNF-dependent sustained, oscillatory Ca 2+ signaling and enhanced MAP kinase activation. This crosstalk is mediated, in part, by synergy between Gβγ, released by TrkB, and Gα q -GTP, released by mGluR5, to enable a previously unidentified form of physiologically relevant RTK/GPCR crosstalk.
- Open Access
- 23 November 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (47) , eabq3363
Control of Gα q signaling dynamics and GPCR cross-talk by GRKs
Numerous processes contribute to the regulation of G protein–coupled receptors (GPCRs), but relatively little is known about rapid mechanisms that control signaling on the seconds time scale or regulate cross-talk between receptors. Here, we reveal that the ability of some GPCR kinases (GRKs) to bind Gα q both drives acute signaling desensitization and regulates functional interactions between GPCRs. GRK2/3-mediated acute desensitization occurs within seconds, is rapidly reversible, and can occur upon local, subcellular activation. This rapid desensitization is kinase independent, insensitive to pharmacological inhibition, and generalizable across receptor families and effectors. We also find that the ability of GRK2 to bind G proteins also enables it to regulate the extent and timing of Gα q -dependent signaling cross-talk between GPCRs. Last, we find that G protein/GRK2 interactions enable a novel form of GPCR trafficking cross-talk. Together, this work reveals potent forms of Gα q -dependent GPCR regulation with wide-ranging pharmacological and physiological implications.
- 23 November 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (47) , eabq3363
Open AccessControl of Gα q signaling dynamics and GPCR cross-talk by GRKs
Numerous processes contribute to the regulation of G protein–coupled receptors (GPCRs), but relatively little is known about rapid mechanisms that control signaling on the seconds time scale or regulate cross-talk between receptors. Here, we reveal that the ability of some GPCR kinases (GRKs) to bind Gα q both drives acute signaling desensitization and regulates functional interactions between GPCRs. GRK2/3-mediated acute desensitization occurs within seconds, is rapidly reversible, and can occur upon local, subcellular activation. This rapid desensitization is kinase independent, insensitive to pharmacological inhibition, and generalizable across receptor families and effectors. We also find that the ability of GRK2 to bind G proteins also enables it to regulate the extent and timing of Gα q -dependent signaling cross-talk between GPCRs. Last, we find that G protein/GRK2 interactions enable a novel form of GPCR trafficking cross-talk. Together, this work reveals potent forms of Gα q -dependent GPCR regulation with wide-ranging pharmacological and physiological implications.
- 1 April 2017
- Published by American Psychiatric Association Publishing in The Journal of Neuropsychiatry and Clinical Neurosciences
- Vol. 29 (2) , 186-188
Delusional Disorder Arising From a CNS Neoplasm
Erotomania arising from a central nervous system (CNS) neoplasm has not been previously described. Here, we present the first known case, to our knowledge, of erotomania with associated persecutory delusions arising following diagnosis and treatment of a left frontal lobe brain tumor.
- 1 April 2017
- Published by American Psychiatric Association Publishing in The Journal of Neuropsychiatry and Clinical Neurosciences
- Vol. 29 (2) , 186-188
Delusional Disorder Arising From a CNS Neoplasm
Erotomania arising from a central nervous system (CNS) neoplasm has not been previously described. Here, we present the first known case, to our knowledge, of erotomania with associated persecutory delusions arising following diagnosis and treatment of a left frontal lobe brain tumor.
- 1 June 2015
- Published by Elsevier in Developmental Cell
- Vol. 33 (6) , 690-702
Slitrk5 Mediates BDNF-Dependent TrkB Receptor Trafficking and Signaling
- 1 June 2015
- Published by Elsevier in Developmental Cell
- Vol. 33 (6) , 690-702
Slitrk5 Mediates BDNF-Dependent TrkB Receptor Trafficking and Signaling